» Articles » PMID: 24931439

Recent Advances Using Zebrafish Animal Models for Muscle Disease Drug Discovery

Overview
Specialties Chemistry
Pharmacology
Date 2014 Jun 17
PMID 24931439
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Animal models have enabled great progress in the discovery and understanding of pharmacological approaches for treating muscle diseases like Duchenne muscular dystrophy.

Areas Covered: With this article, the author provides the reader with a description of the zebrafish animal model, which has been employed to identify and study pharmacological approaches to muscle disease. In particular, the author focuses on how both large-scale chemical screens and targeted drug treatment studies have established zebrafish as an important model for muscle disease drug discovery.

Expert Opinion: There are a number of opportunities arising for the use of zebrafish models for further developing pharmacological approaches to muscle diseases, including studying drug combination therapies and utilizing genome editing to engineer zebrafish muscle disease models. It is the author's particular belief that the availability of a wide range of zebrafish transgenic strains for labeling immune cell types, combined with live imaging and drug treatment of muscle disease models, should allow for new elegant studies demonstrating how pharmacological approaches might influence inflammation and the immune response in muscle disease.

Citing Articles

Modeling Musculoskeletal Disorders in Zebrafish: Advancements in Muscle and Bone Research.

Dalle Carbonare L, Braggio M, Minoia A, Cominacini M, Romanelli M, Pessoa J Cells. 2025; 14(1.

PMID: 39791729 PMC: 11719663. DOI: 10.3390/cells14010028.


Aligning with the 3Rs: alternative models for research into muscle development and inherited myopathies.

Mehmood H, Kasher P, Barrett-Jolley R, Walmsley G BMC Vet Res. 2024; 20(1):477.

PMID: 39425123 PMC: 11488271. DOI: 10.1186/s12917-024-04309-z.


Zebrafish Models for Skeletal and Extraskeletal Osteogenesis Imperfecta Features: Unveiling Pathophysiology and Paving the Way for Drug Discovery.

Masiero C, Aresi C, Forlino A, Tonelli F Calcif Tissue Int. 2024; 115(6):931-959.

PMID: 39320469 PMC: 11607041. DOI: 10.1007/s00223-024-01282-5.


Cold-induced muscle atrophy in zebrafish: Insights from swimming activity and gene expression analysis.

Ikeda D, Fujita S, Toda K, Yaginuma Y, Kan-No N, Watabe S Biochem Biophys Rep. 2023; 36:101570.

PMID: 37965068 PMC: 10641114. DOI: 10.1016/j.bbrep.2023.101570.


The Zebrafish Embryo as a Model Organism for Testing mRNA-Based Therapeutics.

Bondue T, Berlingerio S, van den Heuvel L, Levtchenko E Int J Mol Sci. 2023; 24(13).

PMID: 37446400 PMC: 10342888. DOI: 10.3390/ijms241311224.


References
1.
Bonaldo P, Braghetta P, Zanetti M, Piccolo S, Volpin D, Bressan G . Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet. 1998; 7(13):2135-40. DOI: 10.1093/hmg/7.13.2135. View

2.
Gibbs E, Clarke N, Rose K, Oates E, Webster R, Feldman E . Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med (Berl). 2013; 91(6):727-37. DOI: 10.1007/s00109-013-0994-4. View

3.
Wallace G, McNally E . Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol. 2008; 71:37-57. DOI: 10.1146/annurev.physiol.010908.163216. View

4.
Lu Q, Cirak S, Partridge T . What Can We Learn From Clinical Trials of Exon Skipping for DMD?. Mol Ther Nucleic Acids. 2014; 3:e152. PMC: 4027981. DOI: 10.1038/mtna.2014.6. View

5.
Flisikowska T, Kind A, Schnieke A . Genetically modified pigs to model human diseases. J Appl Genet. 2013; 55(1):53-64. DOI: 10.1007/s13353-013-0182-9. View